Yung‐Luen Yu

3.3k citations

80 papers · 2.6k indexed · 1 hit paper · h-index 28

Cancer Research top 2%
- MicroRNA in disease regulation 9
- Cancer-related molecular mechanisms research 7
Molecular Biology top 5%
- Epigenetics and DNA Methylation 12
- RNA modifications and cancer 7
- Histone Deacetylase Inhibitors Research 5
Oncology top 5%
- Cancer-related Molecular Pathways 4
Pulmonary and Respiratory Medicine top 5%
Immunology top 10%
- interferon and immune responses 6
Pharmacology
- Drug-Induced Hepatotoxicity and Protection 4

Co-authors: Ruey‐Hwang Chou Ling‐Chu Chang Wei-Chao Chang Shuen‐Ei Chen Mien‐Chie Hung Giou‐Teng Yiang Longfei Huo Wei‐Chien Huang
Cited by: Cancer Research Molecular Biology Oncology
Journals: Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (3 papers)The Journal of Experimental Medicine (1 paper)
Partner nations: Taiwan United States Japan

In The Last Decade

Yung‐Luen Yu

77 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Yung‐Luen Yu

Since Specialization

Citations

This map shows the geographic impact of Yung‐Luen Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yung‐Luen Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yung‐Luen Yu more than expected).

Fields of papers citing papers by Yung‐Luen Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yung‐Luen Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yung‐Luen Yu. The network helps show where Yung‐Luen Yu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yung‐Luen Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yung‐Luen Yu Line = papers co-authored together Yung‐Luen Yu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exploration of shared biomarkers and mechanisms in systemic lupus erythematous and lung cancer via bioinformatics analysis Journal of Translational Autoimmunity ·Chueh-Hsuan Hsu,Shuo-Chueh Chen,Yung‐Luen Yu	2025	0
2	The clinical impact of galectin-8 in drug resistant breast cancer Journal of Cancer ·Yi-Chung Chien,Jiayan Wu,Chun Pang,Ruey‐Hwang Chou,Yung‐Luen Yu	2025	2
3	The in vitro and in vivo skin‐whitening activity of Ectoine through enhanced autophagy in melanocytes and keratinocytes and zebrafish model BioFactors ·Wei‐Chen Jane,Siang‐Jyun Chen,Jhih‐Hsuan Hseu,Xuan‐Zao Chen,Sudhir Pandey,Hsueh‐Wei Chang,Hsin‐Ling Yang,You‐Cheng Hseu,Yung‐Luen Yu	2025	0
4	Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis Cell Death Discovery ·Yi‐Chung Chien,Jiayan Wu,Liang‐Chih Liu,Yung‐Luen Yu	2025	3
5	Alpha-mangostin alleviate renal interstitial fibrosis via suppression of TGF-β1/Smad/ERK signaling axis in vitro and in vivo Biochemical Pharmacology ·Ying-Hsu Juan,Yung‐Luen Yu,Yuan-Pei Tsai,Chu‐Che Lee,Yong‐Syuan Chen,Yi-Hsuan Ting,Jen‐Pi Tsai,Yi‐Hsien Hsieh	2023	10
6	EZH2-mediated epigenetic silencing of tumor-suppressive let-7c/miR-99a cluster by hepatitis B virus X antigen enhances hepatocellular carcinoma progression and metastasis Cancer Cell International ·Chen-Shiou Wu,Yi‐Chung Chien,Chia‐Jui Yen,Jiayan Wu,Li‐Yuan Bai,Yung‐Luen Yu	2023	9
7	The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren’s syndrome, cancers, and cancer metabolism Cancer Cell International ·Chueh-Hsuan Hsu,Yung‐Luen Yu	2023	9
8	The Function of the Mutant p53-R175H in Cancer Cancers ·Yen-Ting Chiang,Yi‐Chung Chien,Yuheng Lin,Hui-Hsuan Wu,Dung‐Fang Lee,Yung‐Luen Yu	2021	65
9	Antiproliferative and Antimetastatic Effects of Praeruptorin C on Human Non–Small Cell Lung Cancer through Inactivating ERK/CTSD Signalling Pathways Molecules ·Chien-Ming Liu,Huan-Ting Shen,Yi-An Lin,Yung‐Luen Yu,Yong-Syuan Chen,Chung‐Jung Liu,Yi‐Hsien Hsieh	2020	16
10	Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells International Journal of Medical Sciences ·Hsiao‐Chun Liu,Chien-Chuan Chiang,Ching-Hsiang Lin,Chien‐Sheng Chen,Chyou-Wei Wei,Shu‐Yu Lin,Giou‐Teng Yiang,Yung‐Luen Yu	2020	16
11	Heme oxygenase-1 mediates BAY 11–7085 induced ferroptosisbreakdown → Cancer Letters ·Ling‐Chu Chang,Shih-Kai Chiang,Shuen‐Ei Chen,Yung‐Luen Yu,Ruey‐Hwang Chou,Wei-Chao Chang	2017	443
12	NLRP3 inflammasome: Pathogenic role and potential therapeutic target for IgA nephropathy Scientific Reports ·Yu-Ling Tsai,Kuo-Feng Hua,Ann Chen,Chyou-Wei Wei,Wen‐Shiang Chen,Cheng-Yeu Wu,Ching‐Liang Chu,Yung‐Luen Yu,Chia-Wen Lo,Shuk‐Man Ka	2017	68
13	The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1 Cancer Chemotherapy and Pharmacology ·Ling‐Chu Chang,Yung‐Luen Yu,Chin-Yu Liu,Yung‐Yi Cheng,Ruey‐Hwang Chou,Min‐Tsang Hsieh,Hui-Yi Lin,Hsin‐Yi Hung,Li-Jiau Huang,Yang‐Chang Wu,Sheng-Chu Kuo	2015	17
14	Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features PLoS ONE ·Yung‐Luen Yu,Kuo‐Jung Su,Ming-Ju Hsieh,Shian-Shiang Wang,Po-Hui Wang,Wei‐Chun Weng,Shun‐Fa Yang	2014	11
15	Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells Molecular Pharmacology ·Te‐Chun Hsia,Chih‐Yen Tu,Yun‐Ju Chen,Ya-Ling Wei,Meng-Chieh Yu,Sheng-Chie Hsu,Shing-Ling Tsai,Wen-Shu Chen,Ming‐Hsin Yeh,Chia-Jui Yen,Yung‐Luen Yu,Tzung-Chi Huang,Chih‐Yang Huang,Mien‐Chie Hung,Wei‐Chien Huang	2013	34
16	The NS3 protease and helicase domains of Japanese encephalitis virus trigger cell death via caspase-dependent and -independent pathways Molecular Medicine Reports ·Giou‐Teng Yiang,YEN-HSIEH CHEN,PEI-LUN CHOU,WEI-JUNG CHANG,Chyou-Wei Wei,Yung‐Luen Yu	2013	21
17	Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors Breast Cancer Research ·Yun‐Ju Chen,Ming‐Hsin Yeh,Meng-Chieh Yu,Ya-Ling Wei,Wen-Shu Chen,Jhen-Yu Chen,Chih-Yu Shih,Chih‐Yen Tu,Chia‐Hung Chen,Te‐Chun Hsia,Pei‐Hsuan Chien,Shu-Hui Liu,Yung‐Luen Yu,Wei‐Chien Huang	2013	61
18	Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor American Journal of Respiratory and Critical Care Medicine ·Tzu-Hua Chang,Meng-Feng Tsai,Kang‐Yi Su,Shang-Gin Wu,Cheng-Po Huang,Sung‐Liang Yu,Yung‐Luen Yu,Chou-Chin Lan,James Chih‐Hsin Yang,Shwu-Bin Lin,Chin-Pyng Wu,Jin‐Yuan Shih,Pan‐Chyr Yang	2010	146
19	Isochaihulactone protects PC12 cell against H2O2 induced oxidative stress and exerts the potent anti-aging effects in D-galactose aging mouse model Acta Pharmacologica Sinica ·Sung‐Liang Yu,Shih-bin Lin,Yung‐Luen Yu,Min-Hui Chien,Kuo‐Jung Su,Ching-ju Lin,Tzong‐Der Way,Giou-Teng Yiang,Chai-Ching Lin,De‐Chuan Chan,Horng‐Jyh Harn,Yi-Lin Sophia Chen	2010	17
20	CREB Is One Component of the Binding Complex of the Ces-2/E2A-HLF Binding Element and Is an Integral Part of the Interleukin-3 Survival Signal Molecular and Cellular Biology ·Wannhsin Chen,Yung‐Luen Yu,Shern-Fwu Lee,Yun-Jung Chiang,Jyh-Rong Chao,Jin-Hwa Huang,Jiao-How Chiong,Chang‐Jen Huang,Ming‐Zong Lai,Hsin‐Fang Yang‐Yen,J. J. Yen	2001	35

About Yung‐Luen Yu

Yung‐Luen Yu is a scholar working on Cancer Research, Molecular Biology and Pharmacology, having authored 80 papers that have together received 2.6k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (12 papers), MicroRNA in disease regulation (9 papers), RNA modifications and cancer (7 papers), Cancer-related molecular mechanisms research (7 papers), interferon and immune responses (6 papers), Histone Deacetylase Inhibitors Research (5 papers), Cancer-related Molecular Pathways (4 papers) and Drug-Induced Hepatotoxicity and Protection (4 papers). The work is most often cited by research in Cancer Research (701 citations), Molecular Biology (1.7k citations) and Oncology (592 citations). Yung‐Luen Yu has collaborated with scholars based in Taiwan, United States and Japan. Frequent co-authors include Ruey‐Hwang Chou, Ling‐Chu Chang, Wei-Chao Chang, Shuen‐Ei Chen, Mien‐Chie Hung, Giou‐Teng Yiang, Longfei Huo, Wei‐Chien Huang, Woei‐Cherng Shyu and Chen‐Shiou Wu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact